Use of Anticoagulant, and Associated Factors of Anticoagulant Refusal Atrial Fibrillation Patients

• Conditions: Atrial Fibrillation

• Registration Number: NCT04062071
• Lead Sponsor: Prince of Wales Hospital, Shatin, Hong Kong

Brief Summary

Atrial fibrillation is a clinically significant cardiac arrhythmia that increases the risk of stroke by 3 to 4 times. Oral anticoagulation has been shown to mitigate stroke risk by two-thirds among patients with AF and is widely recommended in optimizing AF management.Direct oral anticoagulants have also been demonstrated to be superior to warfarin with respect to the risk of fatal bleeding and stroke prevention.

However, the previous study finding highlighted a great gap between current guidelines and the clinical management of AF .Nonetheless, the decision for anticoagulant use is not straightforward.It is worth to investigate the updated prevalence of anticoagulant use, the reasons for not receiving anticoagulant, and the factors independently associated with anticoagulant refusal in patients with non-valvular atrial fibrillation.

Detailed Description

Not available

Study Timeline

• Status Verified: 2019-08
• Study First Submitted: 2019-08-16
• Study First Submitted QC: 2019-08-19
• Last Update Submitted: 2019-08-19
• Study First Posted: 2019-08-20
• Last Update Posted: 2019-08-20
• Study Start: 2019-08-23
• Primary Completion: 2020-03-23
• Study Completion: 2020-03-23

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• diagnosis as atrial fibrillation
• aged ≧18 years
• able to given consent

Exclusion Criteria

• Unable/unwillingness to sign informed consent to study
• mechanical heart valve
• moderate-to-severe mitral stenosis
• Transient atrial fibrillation from reversible cause (e.g., during respiratory tract infection or bronchospasm)
• pregnancy
• hospitalization within 1 month prior to inclusion in the study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The prevalence of anticoagulant use in non-valvular atrial fibrillation patients	August 2019 to March 2020	calculate the prevalence of anticoagulant use in non-valvular atrial fibrillation patients

Secondary Outcome Measures

Name	Time	Method
the rate of the refusal of anticoagulant use	August 2019 to March 2020	calculate the rate of refusal of anticoagulant use in the eligible non-valvular atrial fibrillation patients

Trial Locations

Locations (1)

LIAO, Jiawei; 🇭🇰 Hong Kong, Hong Kong